Health Care • Medicinal Chemicals and Botanical Products
$5.91 ▼ -0.18
(-2.96%)
MKT CAP: $366.0M • VOL: 232.4K
52W L $3 52W H $7
OBIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $33.5M | $2.6M | $2.8M |
| YoY Revenue Growth % | +1169.2% | -4.4% | — |
| Gross Profit | $33.3M | $2.4M | — |
| Gross Margin % | 98.0% | 92.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$51.8M | -$64.3M | -$51.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$52.7M | -$61.0M | -$49.1M |
| EBITDA (Normalized) | -$51.4M | -$64.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$49.0M | -$50.6M | -$46.1M |
| Capital Expenditures (CapEx) | $489.0K | $289.0K | — |
| Free Cash Flow (FCF) | -$49.5M | -$50.8M | -$46.1M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $34.7M | $22.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $63.4M | $33.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OBIO.